All Drug Targets articles – Page 27
-
ArticleNot all neoantigens are created equal
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
-
NewsHow gene regulatory networks maintain FLT3-ITD mutated AML
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
-
ArticleThe first multi-chamber heart organoids developed
The first multi-chamber cardioids derived from hiPSCs have enabled scientists to investigate heart development and defects.
-
NewsAI system produces binding proteins using limited target information
New software can make protein molecules that bind with high affinity and specificity to many biomarkers, including human hormones.
-
NewsThe influence of the immune system on early human lung growth
Understanding the mechanisms in lung formation could develop new therapeutic approaches for respiratory conditions.
-
ArticleNew understanding of the TMEJ pathway in cancer
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
-
NewsNew organoid model of neuroendocrine tumours developed
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
-
NewsPotential small molecule drug could treat multiple sclerosis
The new small molecule targets the glutamate system, reducing MS-like symptoms and repairing damaged myelin in two different animal models.
-
NewsAstrocytes gain neural stem cell properties after brain injury
Astrocyte plasticity is correlated with upregulation of the Galectin 3 protein, which may greatly contribute to biomarker discovery.
-
NewsNew potential drug target is discovered for diabetes treatment
Researchers found heightened SCAN enzyme activity in humans and mice with diabetes results in excessive nitric oxide on insulin receptors.
-
NewsAn altered protein can combat the growth of leukaemia cells
Discovery about the NPM1c variant could lead to new drugs targeting the cell growth of acute myeloid leukaemia.
-
News
The IKAROS protein is crucial for B cell development
By mapping the genome, scientists have discovered how IKAROS enables differentiation of hematopoietic stem cells into B cells.
-
NewsNewly discovered mechanism behind microhaemorrhages
Findings about how erythrocytes interact with brain capillaries offers new potential treatments for brain microhaemorrhages.
-
NewsNovel computational model to study cancer dynamics
An advanced computational model enables scientists to study how cancer cells navigate through blood vessels.
-
ArticleWomen in Stem with Andrea Pfeifer
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership, ...
-
NewsPotential therapeutic target for ventricular fibrillation found
A signalling mechanism for ventricular fibrillation involving the stress kinases p38γ and p38δ has been discovered.
-
NewsPotential of small molecule therapeutics for Barth syndrome
Novel findings about the tafazzin gene offers a potential new target and drug candidate for Barth syndrome.
-
NewsTarget found for pulmonary hypertension treatment
An epigenetic pathway is mediated by a certain protein that could potentially reverse vascular remodelling in pulmonary hypertension.
-
ArticleCombining autotaxin and TGF-β inhibitors in cancer
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and ...
-
News
Improving treatment response to KRAS inhibitors
Eliminating AT1-like cells in experimental models has shown potential to improve KRAS inhibitor treatment for lung adenocarcinoma.